title: [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
abstract: Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between imaging response assessment and survival. Among 1289 patients, imaging consisted of: PET ± CT (35%), CT alone (42%), other/no imaging (24%). Median follow-up was 7.6 years. In unadjusted analyses, positive PET ± CT and CT were prognostic of inferior OS (HR 1.78; 95% CI: 1.16-2.72 and HR 1.61, 95% CI: 1.13-2.29, respectively) and PFS (HR 1.63, 95% CI: 1.21-2.20 and HR 1.45, 95% CI: 1.12-1.89, respectively). Adjusting for FL International Prognostic Index, PET remained predictive of OS (HR 1.54, 95% CI: 1.01-2.36) and PFS (HR 1.54, 95% CI: 1.14-2.07). Residual disease via PET in FL is prognostic of survival in clinical practice.
authors: a Department of Haematology/Oncology , Moores Cancer Center, University of California , San Diego , CA , USA.
authors: Ida
authors: I
authors: Wong-Sefidan
authors: b Statistics, Genentech Inc. , South San Francisco , CA , USA.
authors: Michelle
authors: M
authors: Byrtek
authors: c Biostatistics , RTI Health Solutions , Research Triangle Park , NC , USA.
authors: Xiaolei
authors: X
authors: Zhou
authors: d School of Medicine and Dentistry , University of Rochester , Rochester , NY , USA.
authors: Jonathan W
authors: JW
authors: Friedberg
authors: e Winship Cancer Institute, Emory University , Atlanta , GA , USA.
authors: Christopher R
authors: CR
authors: Flowers
authors: f Department of Medicine, Lymphoma Service , Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
authors: Andrew D
authors: AD
authors: Zelenetz
authors: g Medical Affairs , Genentech Inc. , South San Francisco , CA , USA.
authors: Keith L
authors: KL
authors: Dawson
authors: a Department of Haematology/Oncology , Moores Cancer Center, University of California , San Diego , CA , USA.
authors: Erin
authors: E
authors: Reid
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008224:Lymphoma, Follicular / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D000069283:Rituximab / Q000008:administration & dosage; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18; D000069283:Rituximab
keywords: Follicular lymphoma; PET; prognostic; survival